Ardelyx Inc
NASDAQ:ARDX

Watchlist Manager
Ardelyx Inc Logo
Ardelyx Inc
NASDAQ:ARDX
Watchlist
Price: 4.395 USD -0.68%
Market Cap: 1.1B USD

Operating Margin
Ardelyx Inc

-11%
Current
-615%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-11%
=
Operating Profit
-39.6m
/
Revenue
361.7m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Ardelyx Inc
NASDAQ:ARDX
1.1B USD
-11%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
332.6B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
165.1B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
139.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
128.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.9B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Ardelyx Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

Ardelyx Inc. is a biopharmaceutical company that operates at the nexus of innovative drug development, focusing primarily on pioneering treatments for cardiorenal and gastrointestinal diseases. Founded in 2007, Ardelyx has carved a niche for itself by targeting novel therapeutics to address unmet medical needs. The company's flagship product, tenapanor, exemplifies its core strategy. Tenapanor is designed to treat hyperphosphatemia in patients with chronic kidney disease on dialysis by inhibiting the NHE3 sodium transporter in the gut. This mechanism not only addresses phosphate levels but also showcases Ardelyx's approach of modifying pathways at their source to provide significant clinical benefits. The company navigates a complex landscape fraught with regulatory challenges, but its focused pipeline and ability to secure FDA approval for its products underscore its commitment to improving patient outcomes. Ardelyx generates revenue through the commercialization of its products, partnerships, and licensing agreements. The company primarily monetizes tenapanor, its leading therapeutic, which has gained traction in both U.S. and international markets. While the initial stages of bringing a drug to market involve substantial investment in research and development, regulatory approvals, and marketing, Ardelyx's strategic collaborations further augment its revenue streams. These partnerships, often with larger pharmaceutical entities, provide avenues for both upfront payments and milestone achievements as conditions are met. This multifaceted approach not only sustains the company financially but also enhances its capacity to innovate and expand its therapeutic horizons in the biopharmaceutical industry.

ARDX Intrinsic Value
13.64 USD
Undervaluation 68%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-11%
=
Operating Profit
-39.6m
/
Revenue
361.7m
What is the Operating Margin of Ardelyx Inc?

Based on Ardelyx Inc's most recent financial statements, the company has Operating Margin of -11%.

Back to Top